Literature DB >> 14646544

The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma.

M Sato1, K Harada, Y Yura, M Azuma, H Kawamata, H Iga, H Tsujimoto, H Yoshida, M Adachi.   

Abstract

A patient with histopathological recurrent oral cancer with well-differentiated squamous cell carcinoma, was treated with differentiation- and apoptosis-inducing agent, vesnarinone, per os at a dose of 180 mg/day for 56 days and then at a dose of 60 mg/day for 93 days. The vesnarinone administration caused complete remission of the tumour. It has been found by immunohistochemical staining and PCR-SSCP analysis that the recurrent tumour has wild type p53 gene and relative high level of LeY expression as well as DNA fragmentation in the cancer cells, as assessed by nick-end labelling. These findings suggest that the cure of oral squamous cell carcinoma observed in this case might be associated with induction of differentiation and apoptosis of cancer cells by vesnarinone.

Entities:  

Year:  1997        PMID: 14646544     DOI: 10.1023/a:1026493205097

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  3 in total

1.  Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line.

Authors:  F Omotehara; H Kawamata; D Uchida; S Hino; K Nakashiro; T Fujimori
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

2.  Enhanced killing of SCC17B human head and neck squamous cell carcinoma cells after photodynamic therapy plus fenretinide via the de novo sphingolipid biosynthesis pathway and apoptosis.

Authors:  Nithin B Boppana; Ursula Stochaj; Mohamed Kodiha; Alicja Bielawska; Jacek Bielawski; Jason S Pierce; Mladen Korbelik; Duska Separovic
Journal:  Int J Oncol       Date:  2015-02-26       Impact factor: 5.650

3.  Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.

Authors:  Daisuke Uchida; Tomitaro Onoue; Nasima-Mila Begum; Nobuyuki Kuribayashi; Yoshifumi Tomizuka; Tetsuya Tamatani; Hirokazu Nagai; Youji Miyamoto
Journal:  Mol Cancer       Date:  2009-08-12       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.